NO20074859L - Nanopartikulaere formuleringer av docetaxel og analoger derav - Google Patents

Nanopartikulaere formuleringer av docetaxel og analoger derav

Info

Publication number
NO20074859L
NO20074859L NO20074859A NO20074859A NO20074859L NO 20074859 L NO20074859 L NO 20074859L NO 20074859 A NO20074859 A NO 20074859A NO 20074859 A NO20074859 A NO 20074859A NO 20074859 L NO20074859 L NO 20074859L
Authority
NO
Norway
Prior art keywords
docetaxel
analogs
nanoparticulate formulations
nanoparticulate
formulations
Prior art date
Application number
NO20074859A
Other languages
English (en)
Inventor
Elaine Liversidge
Gary Liversidge
Scott Jenkins
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20074859L publication Critical patent/NO20074859L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet sammensetninger av nanopartikulært docetaxel eller en analog derav. Sammensetningene som omfatter et nanopartikulært docetaxel eller en analog derav, og minst én overflatestabilisator, kan brukes ved behandlingen av cancer.
NO20074859A 2005-02-24 2007-09-24 Nanopartikulaere formuleringer av docetaxel og analoger derav NO20074859L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65593405P 2005-02-24 2005-02-24
PCT/US2006/006535 WO2006091780A2 (en) 2005-02-24 2006-02-24 Nanoparticulate formulations of docetaxel and analogues thereof

Publications (1)

Publication Number Publication Date
NO20074859L true NO20074859L (no) 2007-11-26

Family

ID=36928029

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074859A NO20074859L (no) 2005-02-24 2007-09-24 Nanopartikulaere formuleringer av docetaxel og analoger derav

Country Status (14)

Country Link
US (1) US20060188566A1 (no)
EP (1) EP1855659A2 (no)
JP (1) JP2008531591A (no)
KR (1) KR20080003322A (no)
CN (1) CN101160118A (no)
AU (1) AU2006216640A1 (no)
BR (1) BRPI0608173A2 (no)
CA (1) CA2598441A1 (no)
EA (1) EA015987B1 (no)
IL (1) IL185292A0 (no)
MX (1) MX2007010394A (no)
NO (1) NO20074859L (no)
WO (1) WO2006091780A2 (no)
ZA (1) ZA200706783B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
WO2006097793A2 (en) * 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
CN101495096A (zh) 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
NZ549831A (en) * 2006-09-11 2009-03-31 Auckland Uniservices Ltd Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20090022727A1 (en) * 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
WO2008118754A2 (en) * 2007-03-23 2008-10-02 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
JP2010530872A (ja) * 2007-06-22 2010-09-16 サイドース・エルエルシー Ｔｗｅｅｎ８０を含まないドセタキセル可溶化製剤
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
EP2205215A2 (en) * 2007-10-01 2010-07-14 Intas Pharmaceuticals Limited Docetaxel injectable composition, being absolutely free of ethanol
AP2895A (en) * 2007-12-24 2014-05-31 Sun Pharma Advanced Res Co Ltd Nanodispersion
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20150136137A (ko) * 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
WO2010080754A2 (en) * 2009-01-06 2010-07-15 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
WO2010138539A2 (en) 2009-05-27 2010-12-02 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US8778364B2 (en) 2009-06-19 2014-07-15 Sun Pharma Advanced Research Company Ltd. Nanodispersion of a drug and process for its preparation
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20120225825A1 (en) * 2009-11-23 2012-09-06 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
FR2952936B1 (fr) * 2009-11-26 2011-11-25 Flamel Tech Polymere de type acrylique ou methacrylique comprenant des greffons alpha-tocopherol
CN101773480B (zh) * 2010-01-19 2012-03-14 山东大学 含有多西他赛的纳米结晶制剂及其冻干剂的制备方法
WO2011123393A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP2863897B1 (en) * 2012-06-21 2019-06-19 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
US9018246B2 (en) * 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014137797A2 (en) * 2013-03-04 2014-09-12 Transtech Pharma, Llc Stable glucokinase activator compositions
CN103100087B (zh) * 2013-03-04 2014-09-10 中国科学院上海硅酸盐研究所 磷酸钙/有机物复合纳米颗粒的制备方法
CN107823721B (zh) * 2013-05-02 2021-01-29 德国凯德诺有限责任公司 球囊表面涂层
EP3013954A1 (en) * 2013-06-27 2016-05-04 Université de Namur Hybrid alginate-silica beads and method for obtaining them
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
KR20160118317A (ko) 2014-02-03 2016-10-11 아푸라노 파마수티컬스 게엠베하 천연 재료의 나노현탁액 및 그의 제조 방법
ES2763318T3 (es) * 2014-10-06 2020-05-28 Mayo Found Medical Education & Res Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
MX376617B (es) * 2014-12-01 2025-03-07 Innoup Farma S L Nanopartículas para encapsular compuestos, su preparación y sus usos
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105581996B (zh) * 2016-02-23 2018-03-27 广西梧州制药（集团）股份有限公司 一种去水卫矛醇微囊及其制备方法
SG10201913409VA (en) 2016-04-04 2020-03-30 Crititech Inc Methods for solid tumor treatment
JP6960637B2 (ja) * 2016-10-05 2021-11-05 国立大学法人東北大学 リンパ行性薬剤投与法で有効な薬剤
CN106588902B (zh) * 2016-11-29 2019-07-02 昌吉学院 一种紫杉醇抗癌药物、其制备方法及应用
JP2020514359A (ja) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CN115919815A (zh) * 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
KR20200132963A (ko) 2018-03-16 2020-11-25 디에프비 소리아, 엘엘씨 탁산의 나노입자를 사용하는 자궁경부 상피내 신생물 (cin) 및 자궁경부 암의 치료를 위한 국소적 요법
WO2019200084A1 (en) * 2018-04-11 2019-10-17 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
CN110292574A (zh) * 2019-08-02 2019-10-01 江苏红豆杉药业有限公司 一种抗肠癌药物组合物及其应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20250025471A1 (en) * 2022-04-14 2025-01-23 Wisdom Pharmaceutical Co., Ltd Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4638067A (en) * 1982-09-09 1987-01-20 Warner-Lambert Co. Antibacterial agents
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
AU8889998A (en) * 1998-08-21 2000-03-14 Pharmachemie B.V. Water soluble analogs and prodrugs of paclitaxel
US7939105B2 (en) * 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
AU2002214583A1 (en) * 2000-10-11 2002-04-22 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Also Published As

Publication number Publication date
JP2008531591A (ja) 2008-08-14
US20060188566A1 (en) 2006-08-24
KR20080003322A (ko) 2008-01-07
WO2006091780A2 (en) 2006-08-31
CA2598441A1 (en) 2006-08-31
MX2007010394A (es) 2008-02-19
EP1855659A2 (en) 2007-11-21
WO2006091780A3 (en) 2007-01-11
BRPI0608173A2 (pt) 2010-11-09
EA200701793A1 (ru) 2008-02-28
AU2006216640A1 (en) 2006-08-31
EA015987B1 (ru) 2012-01-30
ZA200706783B (en) 2008-10-29
IL185292A0 (en) 2008-02-09
CN101160118A (zh) 2008-04-09

Similar Documents

Publication Publication Date Title
WO2006091780A3 (en) Nanoparticulate formulations of docetaxel and analogues thereof
NO20082376L (no) Farmasoytiske sammensetninger
NO20075148L (no) Anti-proliferativ kombinasjonsterapi med andvendelse av visse platinum-baserte kjemoterapeutiske midler og taxaner
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
WO2009009620A3 (en) Acellular tissue matrix compositions for tissue repair
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
EP2081957A4 (en) PEG-MODIFIED EXENDIN OR EXENDINANALOGONE AND COMPOSITIONS AND APPLICATION THEREOF
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
UA104605C2 (uk) Аналоги глюкагону
ATE553792T1 (de) Medizinische vorrichtungen mit verbundstoffen
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
EP1977004A4 (en) ANGIOGENIC TYROSYL-TRNA SYNTHETASE COMPOSITIONS AND METHOD
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
IL196965A (en) Analogues of (r, r) or (s, r) phenoterol, their pharmaceutical composition containing them and their use for the treatment of heart failure
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
KR102560772B9 (ko) 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
WO2008118754A3 (en) Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
ATE500835T1 (de) Entzündungshemmende zusammensetzungen und anwendungsverfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application